vimarsana.com

Page 3 - நடவடிக்கை விழிப்பூட்டல்கள் ப்லஸ் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

AT&T Rises as Analysts Laud $43 Billion Discovery Deal

Salesforce Gains on Morgan Stanley Upgrade to Overweight

Amazon Gets Price-Target Lift on Ample Services Growth Potential

Amazon Gets Price-Target Lift on Ample Services Growth Potential TheStreet 53 mins ago © TheStreet Amazon Gets Price-Target Lift on Ample Services Growth Potential Amazon received a price-target lift from analysts at Citigroup on what the bank s research team sees as ample room for growth in its B2B services. Popular Searches Citigroup analyst Jason Bazinet raised his one-year price target to $4,175 from $3,750, held his buy rating and maintained his position of Amazon being his favorite internet stock amid what he sees as strong potential growth in its business-services platforms. At last check, shares of Amazon were up 0.97% at $3,182.61. The stock touched a 52-week high of $3554 following its most recent earnings report.

Microsoft Falls Despite Beating Quarterly Estimates

Microsoft Falls Despite Beating Quarterly Estimates Microsoft topped analysts fiscal third quarter earnings and revenue expectations. Author: Original: Shares of Microsoft  ( MSFT) - Get Report were falling Tuesday after the tech giant reported its fiscal third-quarter results. The Redmond, Washington software giant reported fiscal third-quarter earnings of $1.95 per share on revenue of $41.7 billion. Analysts were expecting earnings of $1.77 per share on revenue of $40.83 billion.  Follow TheStreet s live blog of Microsoft s earnings. However, Microsoft shares were down 3.4% to $252.96 after hours on Tuesday. They are up 13.7% year to date, versus a gain of 11.5% for the S&P 500 over the same time period. 

Bristol-Myers Gastric-Cancer Treatment Cleared by FDA

Bristol-Myers Gastric-Cancer Treatment Cleared by FDA Bristol-Myers Squibb s Opdivo with chemotherapy was cleared by the FDA to treat patients with advanced gastric cancer. Author: Bristol-Myers Squibb  ( BMY) - Get Report shares rose Friday after the Food and Drug Administration cleared the health-care giant to market Opdivo as a treatment for gastric cancer. Opdivo as an injection combined with chemotherapy was cleared by the FDA to treat patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma, the company said.  The approval is based on a Phase 3 trial. “Historically, there has been little progress for patients diagnosed with these metastatic gastroesophageal adenocarcinomas,” said Adam Lenkowsky, general manager of oncology at the New York company.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.